Pembrolizumab monotherapy for high-risk, non-muscle-invasive bladder cancer

Lancet Oncol. 2021 Sep;22(9):e379. doi: 10.1016/S1470-2045(21)00390-9.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antineoplastic Agents, Immunological* / adverse effects
  • Humans
  • Urinary Bladder Neoplasms* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • pembrolizumab